NantOmics
$1.8Bpaper valuation
// OVERVIEW
NantOmics is the computational arm of Patrick Soon-Shiong's NantWorks constellation — a $1.8 billion bet that cancer moonshots require proprietary genomic databases nobody else can access. The company processes genomic sequencing data for NantHealth's clinical trials and built a molecular profiling platform that has consumed a decade of capital without demonstrating commercial traction independent of its parent entity.
// HQ
Culver City, United States
// STATUS
PRIVATE
// FOUNDED
2016
// TIER
The Unicorn Herd · $1B – $9.9B
// PRIMARY SECTOR
biotechnology
// FOUNDERS
// SECTORS SERVED
// TECHNOLOGY
The platform combines whole-genome sequencing with proteomic analysis to generate molecular tumor profiles. NantOmics claims its GPS Cancer test identifies actionable mutations faster than Foundation Medicine or Tempus, though the actual clinical validation data remains largely unpublished. The computational infrastructure processes petabyte-scale genomic datasets — impressive engineering solving a problem the market has not yet agreed to pay for at scale.
// WOWLS ASSESSMENT
NantOmics has been operationally invisible since its 2016 launch. No disclosed revenue. No major pharmaceutical partnerships announced. No peer-reviewed publications demonstrating clinical superiority over competing molecular profiling platforms. The valuation appears to be an accounting artifact of NantWorks' internal structure rather than a reflection of standalone enterprise value — Soon-Shiong owns the entire vertical stack and can assign valuations across subsidiaries without external price discovery. Illumina and Thermo Fisher dominate the sequencing infrastructure market. Tempus and Foundation Medicine own the clinical molecular profiling relationships oncologists actually use. NantOmics occupies the awkward middle — too vertically integrated to win third-party customers, too opaque to demonstrate its computational advantage is real.
// WHY WOWLS HUNTS THIS
Because vertical integration is only a moat if someone outside the family is willing to pay for it. NantOmics has never demonstrated that anyone is.
// VALUATION NOTE
Valuation likely reflects internal NantWorks allocation rather than external funding round. No public funding rounds identified. Parent company NantHealth is public (NASDAQ: NH, $200M market cap) but NantOmics financial performance not separately disclosed.
VERDICT: PAPER TIGER — $1.8 BILLION VALUATION WITH ZERO PUBLIC EVIDENCE OF COMMERCIAL TRACTION OUTSIDE THE NANTWORKS ECOSYSTEM AFTER EIGHT YEARS
// PACK DEBATE
// PACK DEBATE — be the first to weigh in
Google account required — no spam, no nonsense
// LOADING INTEL…
// BROADCAST INTEL
// SIMILAR TARGETS
// INTEL UPDATED: MAY 2026
// INTELLIGENCE DISCLAIMER: Assessments represent editorial opinion based on publicly available data including filings, press reports, and market data as of the date shown. Valuations are approximate. Not financial or investment advice.
// FULL NETWORK ACCESS
🚀 Founder Briefing: Instantly sort investors by Sector, Stage, & Round — direct links to websites for all 1,030 unicorns & backing VCs included.
Don't just track NantOmics.
Master the entire 1,030 unicorn company intelligence network.
Stop analyzing tech monopolies one page at a time. Instantly filter, sort, and isolate the exact venture capital firms, angel investors, and corporate funds backing your specific market vertical. Find investors that fit your sector and deploy your pitch with direct outbound links to every target asset in the database — 1,030 targets total.
Acquire Intel →// 5 TIERS · PAYPAL SECURED
// ENGAGE THE FULL ARSENAL
Done reading on NantOmics?
Unlock the entire 1,030-company hitlist and 1,030 investor contacts.
Full structural breakdowns. Founder dossiers. VC outreach data. Threat-level intel updated continuously.
→ Deploy 5-Tier Order Form// ARBAN · ZUUN · MINGHAN · TUMEN · KHAN